目的探讨二甲双胍联合低聚果糖对妊娠期糖尿病(GDM)患者血糖达标率及妊娠结局的影响。方法选取2018年6月至2020年6月衡阳市中医医院收治的71例GDM患者作为研究对象,采用随机数字表法分为对照组(n=35)和观察组(n=36)。两组行一般治疗,对...目的探讨二甲双胍联合低聚果糖对妊娠期糖尿病(GDM)患者血糖达标率及妊娠结局的影响。方法选取2018年6月至2020年6月衡阳市中医医院收治的71例GDM患者作为研究对象,采用随机数字表法分为对照组(n=35)和观察组(n=36)。两组行一般治疗,对照组给予二甲双胍治疗,观察组在对照组基础上加用低聚果糖治疗。比较两组治疗后血糖达标率[空腹血糖(FBG)、餐后2 h血糖(2hPBG)、糖化血红蛋白(HbA1c)]及治疗前后炎症介质、总胆红素(TBil)、胆固醇(TC)及尿酸(UA)水平及和妊娠结局。结果治疗后,观察组患者FBG(61.11%)、2 h PBG(58.33%)、HbA1c(63.89%)达标率高于对照组FBG(37.14%)、2 h PBG(34.29%)、HbA1c(40.00%),差异有统计学意义(P<0.05);治疗后,两组C反应蛋白(CRP)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)较治疗前下降,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组TBil水平较治疗前提高,且观察组高于对照组,两组TC、UA水平较治疗前下降,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者不良妊娠结局发生率(13.89%)低于对照组(40.00%),差异有统计学意义(P<0.05)。结论二甲双胍联合低聚果糖用于治疗GDM患者效果较好,能有效提高患者血糖达标率,减轻炎症反应,改善CRP、IL-6、TNF-α水平,优化妊娠结局。展开更多
Human gastrointestinal health may be improved by the consumption of prebiotic food ingredients such as fructooligo-fructoses. A study was initiated to determine the effect of fructooligofructoses of different chain le...Human gastrointestinal health may be improved by the consumption of prebiotic food ingredients such as fructooligo-fructoses. A study was initiated to determine the effect of fructooligofructoses of different chain lengths on gastrointes-tinal parameters. Nineteen healthy subjects aged 20 - 57 y took part in a 10-week cross-over designed study. Subjects consumed either inulin or oligofructose for 3 weeks followed by a 2-week washout period between treatments. Stool samples were collected five times (baseline, 2 treatments, 2 washout) and analyzed for bifidobacteria. Daily records were kept for stool frequency, stool consistency and flatulence frequency. Bifidobacteria counts (cfu/ml) were higher (trending toward significance) during inulin and oligofructose intakes (1.2 × 107 ± 4.8 × 107 and 2.0 × 108 ± 4.7 × 108) and washout periods (2.9 × 106 ± 6.5 × 106 and 1.1 × 107 ± 1.6 × 107) than baseline counts (2.2 × 105 ± 5.1 × 105 and 2.9 × 106 ± 6.5 × 106), respectively. Inulin and oligofructose treatment periods had a significant effect on stool consistency (watery/very hard) and flatulence frequency, but not stool frequency, when compared to baseline (P < 0.05). Further research is needed to confirm these results due to small sample size and the need for a longer washout period between treatments.展开更多
文摘目的探讨二甲双胍联合低聚果糖对妊娠期糖尿病(GDM)患者血糖达标率及妊娠结局的影响。方法选取2018年6月至2020年6月衡阳市中医医院收治的71例GDM患者作为研究对象,采用随机数字表法分为对照组(n=35)和观察组(n=36)。两组行一般治疗,对照组给予二甲双胍治疗,观察组在对照组基础上加用低聚果糖治疗。比较两组治疗后血糖达标率[空腹血糖(FBG)、餐后2 h血糖(2hPBG)、糖化血红蛋白(HbA1c)]及治疗前后炎症介质、总胆红素(TBil)、胆固醇(TC)及尿酸(UA)水平及和妊娠结局。结果治疗后,观察组患者FBG(61.11%)、2 h PBG(58.33%)、HbA1c(63.89%)达标率高于对照组FBG(37.14%)、2 h PBG(34.29%)、HbA1c(40.00%),差异有统计学意义(P<0.05);治疗后,两组C反应蛋白(CRP)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)较治疗前下降,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组TBil水平较治疗前提高,且观察组高于对照组,两组TC、UA水平较治疗前下降,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者不良妊娠结局发生率(13.89%)低于对照组(40.00%),差异有统计学意义(P<0.05)。结论二甲双胍联合低聚果糖用于治疗GDM患者效果较好,能有效提高患者血糖达标率,减轻炎症反应,改善CRP、IL-6、TNF-α水平,优化妊娠结局。
文摘Human gastrointestinal health may be improved by the consumption of prebiotic food ingredients such as fructooligo-fructoses. A study was initiated to determine the effect of fructooligofructoses of different chain lengths on gastrointes-tinal parameters. Nineteen healthy subjects aged 20 - 57 y took part in a 10-week cross-over designed study. Subjects consumed either inulin or oligofructose for 3 weeks followed by a 2-week washout period between treatments. Stool samples were collected five times (baseline, 2 treatments, 2 washout) and analyzed for bifidobacteria. Daily records were kept for stool frequency, stool consistency and flatulence frequency. Bifidobacteria counts (cfu/ml) were higher (trending toward significance) during inulin and oligofructose intakes (1.2 × 107 ± 4.8 × 107 and 2.0 × 108 ± 4.7 × 108) and washout periods (2.9 × 106 ± 6.5 × 106 and 1.1 × 107 ± 1.6 × 107) than baseline counts (2.2 × 105 ± 5.1 × 105 and 2.9 × 106 ± 6.5 × 106), respectively. Inulin and oligofructose treatment periods had a significant effect on stool consistency (watery/very hard) and flatulence frequency, but not stool frequency, when compared to baseline (P < 0.05). Further research is needed to confirm these results due to small sample size and the need for a longer washout period between treatments.
